Drug Profile
Research programme: monoclonal antibody therapeutics - Eisai Inc/University of Pennsylvania
Latest Information Update: 23 Jan 2020
Price :
$50
*
At a glance
- Originator Morphotek; University of Pennsylvania
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 23 Dec 2008 Preclinical trials in Solid tumours in USA (Parenteral)